Microparticles (MPs) aresmallmembrane vesiclesgeneratedby essentiallya ll cell types. In the plasma,most MPsa re derived from platelets,but those from othersources, particularlyleukocytes(macrophages,lymphocytes, andneutrophils), endothelial cells, and even smooth musclecells can be detectedand appear to playanimportantrole in normal physiologyand various diseases. In previous work we analyzed the proteome of MPs generatedfromisolated platelets (plateletMPs).Here,we reporton ac omparative analysis of microparticlesi solated from plasma (plasma MPs) versus plateletM Pu sing twoc omplementary methods of comparative analysis. Thef irstm ethod,s pectral count analysis, yielded 21 proteins detectedinplasma MPs (with atotal spectral count of 10 or greater) that were essentiallyabKeywords Secretion /exocytosis,plateletactivation markers, vascularcell markers sent in plateletMPs (with atotal spectral count of 1or0). An additional twop roteins (von Willebrand Factor,a lbumin) were presentinboth types of MPsbut enrichedinthe plasma MPs.The second method,i sotope-codeda ffinityt ag (ICAT)l abeling of proteins, supportedt he spectral countr esults fort he more abundantp roteins and provided better relativeq uantitationo f differentiallye xpressedp roteins. Proteins presento nlyi nt he plasma MPsincludeseveral associated with apoptosis (CD5-like antigen, galectin3binding protein, several complement components), iron transport(transferrin, transferrin receptor,haptoglobin),immune response (complementcomponents, immunoglobulin Jand kappa chains), and the coagulationprocess (protein S, coagulation factor VIII).
Introduction
Microparticles( MPs) are small subcellularm embranous vesiclesreleased by essentiallyall celltypes, especiallywhen activatedorunder stress. Theyinclude ectosomes, generated from the ectocytosis( or blebbing) of the plasma membrane and exosomes, released by fusion of intracellularmultivesicular endosomeswith the cellsurface(1, 2). In plasma, MPswere discovered as acomponent of the blood that promotes coagulation due to the presenceofanionic phospholipids on their outer surface(3). These anionic phospholipids, later determinedt ob em ostly phosphatidylserine,a re noww idely used to detect MPsf rom blood samples using flowcytometrybased on their affinity for fluorescentlylabeled annexin V. The cellular source of the microparticles is determined by cell-specificmarkers detected by flow cytometry(4). Forexample, MPswith CD41(glycoprotein IIb) expression arebelievedtobegenerated by platelets. Using this method,microparticlesfrom platelets,erythrocytes, endothelial cells, neutrophils, lymphocytesa nd even smooth muscle cells have beend etected in the plasma.I nh ealthyi ndividuals, over 90%ofthese MPsoriginatefrom platelets (4), and under awide rangeofpathological conditions the totalnumber of microparticlesa nd the number originating from variousc ellp opulation arealtered (5, 6).
Traditionally, the presence of microparticlesinthe plasma is consideredasign of cellularactivation and/or damage generated by the random blebbing of cellmembranes.However,significant evidencehas accumulated to indicatethat MPscontain aunique set of proteins (7, 8) and inflammatoryfactors(9) that have important biological functions.F or example, rapid secretion of IL-1 β from THP-1 monocyteso ccursv ia MP releasei ne ctosomes, and this could be ageneral mechanism of releasefor secretedproteinsthat lackthe conventional signal peptide for secretoryp roteins( 10). MPsi solated eitherf rom plasmao rt he supernatants of stimulated cells have awide variety of effects on cellular function (11). These effects include increased expression of adhesion moleculesonendothelial cells and monocytes(12), stimulation of cytokinerelease (13, 14) , altering vascular reactivity (15), inducing angiogenesis (16), decreasing the response to inflammatorymediators(17), and fibrin formation (18, 19) . The effects vary depending on the cellular sourceofthe microparticles, the method to generate themand the cells (or tissue)affected (11).
While many groups have studiedthe effects of these MPson variouscells, the protein composition of plasma MPs is largely unknown except forthe presenceofafew cell-surface markers. Recently,w ea nalyzedt he proteome of platelet-derivedm icroparticlesa nd identified 578 proteins (20) .T his current study examinest he proteomic composition of plasma MPsw ith a focuso np roteinsn ot found in platelet-derivedM P. Microparticlesw ere isolatedfrom plasmab ygel filtration and ultracentrifugation. Twom ethods were used to determine the relative protein abundance; (1) MS-MS spectralc ount and (2) ICATbasedc omparative analysis. Fort he MS-MS spectralc ount, microparticle proteins from plasmaand plateletMPs were prepared and analyzed using amethodconsisting of electrophoresis, trypsin digestion, and online liquidchromatography-mass spectrometry(LC/MS)using alinear ion trap mass spectrometer. We identifiedpeptidesfrom 21 proteins in plasma MPs (with atotal spectralc ount of 10 or greater) thatw ere essentiallya bsent in plateletMPs (with atotal spectralcount of 0or1). Tenofthe 21 proteins were determinedtobeenriched in the plasma MPstoa statistically significant extent. Twoa dditional proteins were present in both typesofMPs butwere moreabundant in the plasma MPs. ForI CAT-basedc omparative analysis, proteins from these twosources were differentiallylabeled with isotope-coded affinity tag (ICAT) reagents, mixed,delipidatedbyP AGE, trypsind igested, enrichedf or ICAT-labeledp eptides, and analyzed by LC/MS.T his method supported the resultsf rom spectral count analysis and providedadditional quantitative information about the moreabundant proteins. It also yielded detection of hemoglobin as an additional protein enrichedinplasma MPs.
Materials andmethods
Isolationofplatelets, platelet-derived MPs, and plasmaderived MPs Platelets and platelet-derivedM Ps were isolateda sd escribed (20) .B riefly, human blood wasc ollectedb yv enipuncturei nto 1/10 volume of an acid-citrate-dextrose (85 mM trisodium citrate, 83 mM dextrose,and 21 mM citric acid) solution. Plateletrichplasma (PRP) wasobtained by centrifugation at 110×g for 15 minutes( min).P latelets were pelletedb yc entrifugation at 710×g for 15 min and the supernatant,p latelet-poorp lasma (PPP),was retained forisolation of plasma MPs (seebelow). The plateletpelletwas washedthreetimes, re-suspended in 10 ml of Ty rode's buffer,and centrifugedone additional timeat110 × g to remove remaining red blood cells and deadc ells. To generate platelet-derivedm icroparticles, ADP( 10 µ Mf inalc oncentration) wasadded to the plateletsuspension for 10 min (20) .Platelets were removedbycentrifugation (710xg for 15 min) and platelet-derivedMPs were pelletedbycentrifugation at 150,000 × g for 90 min at 10°C.
Plasma-derivedM Ps were isolatedb yg el filtration chromatography followedb yu ltracentrifugation.B riefly, platelet-poor plasma(PPP) wascentrifugedtwice to remove residualcellsand cell debrisat710 x g and25°Cfor 15 min. This plasmawas then applied to aSephacryl  S-500 HR (GEHealthcare, Piscataway, NJ, USA) gelfiltration column and MP-containing fractions were concentrated by ultracentrifugation at 150,000 x g for 90 min at 10°C.
ICAT-labeling, electrophoresis, digestion, and peptide enrichment
Comparativeq uantitation of proteins following ICAT-labeling wasp erformed as depictedi nF igure1 B. Briefly, platelet-and plasma-derived microparticle pellets were re-suspended in PBS (Phosphatebuffereds aline,p H7 .4), and protein concentration wasd etermined. Solutionsc ontaining equivalent protein amountso fp aired samples (plasma MP and platelet-derived MP) were lyophilizedand re-suspended in a1%SDS denaturing buffer.Samples were labeledand processedusing the ICATlabeling kit (AppliedB iosystems, Foster City,C A, USA) as instructed with the following modifications. The initial labeling reaction wasperformed at halfofthe recommendedvolume, protein amount, and ICATr eagentb ecauseo ft he lowa mounto f protein obtained from each plasma MP preparation. The differentially-labeledproteinswere mixed,applied to the gel, electrophoresed,and cut from the gel as describedabove except thatthe loading buffer didn ot contain the reducing agent or SDS.The proteins were digestedwith trypsin, extracted fromthe gel and processedthrough the avidin columnasrecommendedbymanufacturer.The samples were lyophilizedand reconstituted to 20 µ l with0.1% acetic acid for mass spectrometryanalysis. This procedure wasrepeated three timeswith plasma MPs labeledwith the light ICAT reagent for twoofthese samples and labeled with the heavy ICATreagentinthe third.
Liquidchromatography/massspectrometry(LC/MS) and protein identification
Sampleswere loadedonto a360 µ mo.d. ×75 µ mi.d. microcapillaryfused silica precolumn packedwith irregular5-20 µ mC18 resin. After sample loading, the precolumn wasw ashed with 0.1%acetic acidfor 15 min to remove anybuffersalts or gelcontaminants. The precolumn wasthen connectedtoa360 µ mo.d. ×50 µ mi.d. analytical columnpacked with regular5µ mC18 resin constructedw ith an integrated electrospray emittert ip. Sampleswere gradient eluted at aflowrateof60nL/min withan 1100 series binaryHPLCsolvent delivery system(Agilent,Palo Alto, CA,U SA)d irectly througha ne lectrospray ionization source interfaced to aFinnigan LTQion trapmassspectrometer (Thermo ElectronCorp, San Jose, CA, USA). The HPLC gradient used wasinitially100%A,5%Bat5min, 50% Bat220 min, 100% Bat240 min, and restored to 100% Aat280 min (solvent A=0.1 Ma cetic acid, solvent B=70% acetonitrile in 0.1 M acetic acid).T he LTQm asss pectrometerw as operated in the data-dependent mode in whichfirst an initialMSscan recorded the mass to charge ( m / z )r atios of ions over the mass range . MS generated files (.raw) were converted into .mzXMLfilesand imported into MSight. A) Sampleportion of theplotofintensitiesofm/z 810 to 1020 ions that eluted between 90 and 145 min. B) Peptideswereannotated and relativequantitationand identification(seeSupplementary Ta ble 1a vailableonline at www.thrombosis-online.com). While mostspots appear as pairsofequal intensity,there areseveralwithdifferent intensities (6,9,29, etc.) 300-2,000 Dalton (Da),and then the 10 most abundant ions were automaticallys elected fors ubsequent collisionally-activated dissociation and MS/MS spectrum recorded. All MS/MS data were searched against ah uman protein database downloaded from the NCBI database (www.ncbi.nlm.nih.gov) on August24, 2004 using the SEQUEST  program (Thermo ElectronCorp.). Forunlabeled peptides, astatic modification of 57 Da for cysteine residueswas employed in the search parameters.For ICATlabeledpeptides, astatic modification of 227.127w as used for the light isotope labeland an additional 9Dafor the heavy ICATlabeledp eptides. Peptide identifications were made basedo n fully tryptic peptides, usingaf irst-pass filtering of standard criteria as previouslydescribed (22),including cross correlation values ≥ 2.0 (+1c harge),2 .2 (+2c harge) and 3.5 (+3c harge). Proteina ssignments required at leastt wo MS/MS spectra matchesthat passedthe above criteria. Manual validation of at leastone MS/MS spectrum -peptide sequence match per protein wasperformed forall proteins thatwere determinedtobedifferentiallyexpressed.
Comparativeanalysis of unlabeled peptidesusing spectral count
Forthe unlabeled scheme (Fig. 1A) ,all search results not passing the first-passfilterw ere eliminated. Ther emaining numbero f spectra foreach peptide wasdetermined, and the number of total proteins detectedw as calculated. Only proteins with an overall spectral count of 10 or greater were analyzed furtherb yt his method,and all with 1ornoMS-MS scan were considered essentiallyabsent. The ratio of the number of spectra from the plasma MPsversus the plateletMPs wascalculated,log 2transformed, and thenadjusted for an overallratio scoreof1(log 2 =0.00) excluding the vWF-containing peptides. Statistical analysis was performed using the sources tatistical software package R (http://www.r-project.org/).The data from the unlabeled experiments were normalized so allexperiments have the same interquartileranges.Inaddition, log2-transformation wastaken to reduce the skewed distributions. Some spectral countswere zero, so 0.5 wasa dded to all valuesi no rder to allowl og2-transformation. The two-sample t-test wasperformed to examine the significant difference in protein spectral countsbetween plasma and platelet MPs. P<0.05 wasusedtodetermine differentially expressed proteins.
Comparativeanalysis of unlabelled peptidesb yion intensity measurements
Ion intensitiesf or peptides from each of the putative differentiallye xpressed protein were determinedu sing QualB rowser (Thermo ElectronCorp.). Briefly,the twelveLC-MS chromatographsw ere alignedu sing 25 peptidest hat were detected in most, if not all, of the runs. The ion intensities for the five most abundantpeptides(withatotal spectralcount of at least six) from each the putatively differentiallye xpressed protein (based on spectralcount results) were determinedusing am/z rangeof± 0.3 Da.F or each peptide, as tandard two-tailedt -test wasp erformed. In addition, the overallsignificance of each proteinwas determinedbynormalizing the ion intensities for all peptides of aprotein to have equal variances; hence, each peptide can have an equal weight when pooled forexamining the overallsignificance. Treating peptidesa sablock effect, ar andomized block design ANOVA wasapplied to the normalizeddatatodetermine the overallsignificance foragiven protein.
Comparativeanalysis of ICAT-labeled peptidesusing
MSight  Comparativeq uantitation wasp erformed using MSight, freely availablef rom the Swiss Institute of Bioinformatics( www.expasy.org/Msight)( 23). Data files( .RAW) generated using XCalibur Software(Thermo Electron Corp.) were converted to mzXMLf ilesu sing ReAdW (Institute forS ystems Biology, Seattle,W A, USA). These fileswere importedinto MSight, and the peptides were manuallyquantified. The peptides were identifiedusing SEQUEST as described above.Asample representation of the MSight displayfor asmall portion of one of these runs is shown in Figure 2a nd ion intensities canb es een in Supplementary Table1a vailableo nline at www.thrombosisonline.com. Initially, peptides that were detected in allt hree ICAT analyses based on SEQUESTr esults were quantified, if possible.Then, peptides with high ion intensities were quantified and linked backed to SEQUEST results. Attempts to quantify peaks sometimes faileddue to poor signal-to-noise ratios,overlappingpeptides, and ambiguousidentification of agiven peak. Unless otherwisenoted,ICATquantitation resultsare reported if goodpeak quantitation waspossible in at least twoofthe three ICAT runs and labeled alternatively in these tworuns. This led to the quantitation of 94 peptides. Utilizing the differential labeling, the ratios of plasmaM Ps to platelet MPs ICAT-peptide abundances were calculated, alog2transformation of these ratios wasp erformed,a nd adjusted to generate an overalll og2 scoreof0.00, excluding vWF. VWF wasexcludedbecauseitwas evident thatt herew as as ignificant enrichment in the plasma MPs. Duetothe large number of peptides detectedfor this protein and the extent of enrichment, not omitting it would makeit appear thatm ost other proteins were enriched in the platelet MPs. To determine significance, the paired t-test wasu sedt o examine differences in peptide expression intensities between plasma MPsand plateletMPs. P<0.05 wasusedtodetermine differentiallyexpressed peptides.
Results
While alarge majority of the plasma MPs are platelet-derived, MPs from othersources have beenimplicated in normalphysiologya nd under pathologicalc onditions (4, 11). Previously, we have examinedthe plateletMPproteomeand detected578 proteins. In the present study,weisolated MP from plasma and compared them to plateletMPusing twocomplementarytechniques: i) spectral count analysis of unlabeledp roteins/peptidesa nd ii) manualrelativequantitation of ion intensities of ICAT-labeled proteins/peptides.
Relative quantitation of plasma MPsand platelet MPs usingspectral counts
PlasmaMPs and platelet MPs were isolatedfrom three individuals, the proteins processeda nd digested into tryptic peptides whichwere analyzed in duplicate (Fig. 1A) .The MS/MS spectra wassearched using SEQUEST and spectra notpassing first-pass Forproteinswith acumulative spectral count of 10 or more, the relativespectralcounts were compared between plasma MPs and platelet MPs (seeSupplementary Table3availableonline at www.thrombosis-online.com and Table1).The log2ofthe ratio of the spectralcounts wasnormalizedtoanaverage of 0.00 (excluding vWF)which represents the null hypothesis of equalrepresentation of proteins in plasma and platelet MPs. There were 21 proteins for whichpeptideswere detected in plasma MPs but not plateletMPs (spectral count of 1or0); however, only10of these differences were statistically significant (Table 1) .Inaddition, twootherproteins(vWF,albumin) were present in both sets of MPs butenriched in the plasma MPs. There were also11pro-teins enrichedinthe plateletMPs. This apparent enrichment of proteins in the platelet MPsmay simplybedue to the overwhelming spectral count forvWF in the plasma MPs, accounting for roughly 10% of all spectra.This would tend to dilutethe peptides for all other proteins on relative spectral count basis. Complete description of the proteins and the peptide sequences enrichedin the plasma MPs and/or present only in the plasma MPs are in Table2 ,a nd supplementary Table4a tw ww.thrombosisonline.com),respectively. Peptides from threeofthese proteins, complement component 4-binding protein, Fc fragment of IgGbinding protein, Galectin 3-binding protein, and vWF,were confirmed to be overexpressedinplasma-derivedmicroparticlesby analyzing ion intensities( seeS upplementary Table5a vailable online at www.thrombosis-online.com).
Comparativeanalysis of ICAT-labeled proteinsb y manual quantitation of peptide ionintensities
As acomplementaryapproach to examine differences in the protein composition of plateletMPs versusplasma MPs, adifferentialanalysis using isotope labeling wasperformed. MP were differentiallyl abeled and mixed prior to PAGE, trypsin digested, extracted,and analyzed by LC/MS (Fig. 1B) . This wasperformed on three differentsamples,and 94 of the more abundant peptides were quantified(seeSupplementary Table6a vailableonline at www.thrombosis-online.com). The log2 of the ratios of the peptide abundances in plasma MPstoplateletMPs wascalculated,and the averageadjusted to 0.00, excluding the peptides from vWF (Fig. 3) .Peptidesfrom three proteins (albumin, beta globin, and vWF)were consistentlyenriched in plasma MPsversus plateletMPs. The results for vWF and albuminare consistent with thoseobtained from spectralcount analysis. While the spectral countsf or beta globin (and several other hemoglobin proteins) were all about two-foldhigherinthe plasma MPsversus the plateletMPs usingspectralcount, that method wasunable to demonstrate significant enrichment. Several peptidesfrom three proteins,thrombospondin, and integrins α IIb and β 3 ,appeartobe enrichedinthe plateletMP.
ICAT quantitation of differentially expressed peptides based on scan number
In order to confirm the results of the spectral count analysis of unlabelledp roteins, the peptidesf rom all proteins whichw ere present in the plasma MPs (spectral count of 10 or more) and essentiallynot present in the plateletMPs (spectral count of 0or1) were examinedbyICATmethodology (Table 3) .Spectra for peptides for 16 of the 27 proteins were detected in at leastone of the threeI CATa nalyses. Similar to the spectralc ount of the unlabelled samples, therew as ad ramatic difference in spectral countsofthe ICAT-labeledproteinsbetween the twosamples for these "enrichedproteins" with 63 spectra forpeptidesfrom these proteins in the plasma MPs while only2were detected in the plateletMPs (Table 3) .Ofthe 63 peptides identified by SEQUEST, the ion intensitieso f3 3( representing 27 different)p eptides could be quantifiedinatleastone analysis. It is importanttonote that in manyc ases the peptide from the plateletm icroparticle sample wasnot visuallydetected and the backgroundion intensitywas used to calculatethe ratios,thus yielding alower bound. This likelyled to an underestimation of the foldenrichment in plasma MPs. This is particularly true for several peptidest hat had poor signal-to-noise ratios due to lowabundance. Peptides from all of the proteins detectedonlyinthe plasma MP had an adjusted log2scoreofgreater than1.58, representing at least a three-fold increase in concentration.
Peptides from the proteins present in both the plasma MPs and platelet MPs bute nriched in the plasma MPsw ere also examinedu sing ICAT. As described above,v WF and albumin appeared enrichedb yt his method (seeS upplementary Table6 availableonline at www.thrombosis-online.com and Fig. 3 ).
Comparing the resultsf rom the twoa pproaches( spectral countsversus ICAT-label)provides us with awealth of information about the relatives trengths and weaknesseso fe ach. The most obviousstrength of the spectral count approach is its ability to generate alarge numberofprotein differences withoutextensive and time-consuming manualq uantitation. The main strength of the ICAT-basedapproach is its superior quantitation; allowing determination of as little as two-foldd ifferences in abundance. While it is currentlye xtremelyt ime consuming to detectt hese differences, the development and availability of bettersoftwareshould alleviate this problem. It is interesting to note that spectralc ount is able to detect differencesi nl ower abundantpeptides/proteins even when the ion currentdoes not appear above the background. Thesef eatures demonstrate the complementarynatureofthe twoapproaches.
Ve rification of massspectrometric analysis by immunoblots
To verify ther elative quantitationo ft he differentiallye xpressed proteins, immunoblottingfor three proteinso verexperessedinthe plasma MPsw as performed (Fig.4 ) , plasma MPsw ere isolated from plasma andPlatelet MPswere isolated following activationof platelets. The proteinswere separated by PAGE, transferred ontoa membranea nd probedf or complementc omponent 3, galectin 3-binding protein,orvWF.Complementcomponent 3and galectin 3-binding protein were onlydetectable in theplasma MPs. vWFwas greatlyenriched in theplasma MPs, butw as faintlyvisible in the platelet MP followingoverexposureofthe film (data not shown). uals. Of these,10were significantlyenriched while the other11 proteins showedatrend to enrichment butdid not reach statistical significance. Many of these probablyrepresent proteins that are present during the initialformation of the microparticlesand bind to the microparticle complex.B eyond statisticala nalysis, confidencei nt he detectedd ifferences is furthere nhanced by confirmation usingdirect ICAT-based comparison. In addition, there were twoproteinsdetected in both sets of MPs butsignificantly enrichedinplasma MPs basedonspectralcounts.
In our previous report, we identified578 proteins from platelet microparticles(20),w hile in this study,2 29 proteins were detected.The reason for this disparity is explained by the goals and methods. In the previous study, the gelwas sectionedinto 26 equalparts and each wasanalyzedseparatelybyLC-MS allowing detection of low-abundance peptides. In the present report, we were interested in adifferentialanalysis and did not section the gel lane.The previous reportwas based on onesamplefrom as ingle individual.H ere, we analyzed samples from threed onors, each in duplicate.
Seventy-fivepercentofthe proteins detectedinplateletMPs in this studyw ere also detected in our previous study ( Fig. 5) . The 87 most abundant proteins detectedi no ur previous study (based on spectralcount) were alsodetected in the current analysis of plateletMPs. While approximately 25% of the platelet MP proteins from the previous work were notd etected in this study, as ignificant fraction of these were hypothetical proteins and manymay simplyreflect differences in their annotation within the different databases searched.Comparing plasma MPstothe plateletMPs, 75%ofthe proteins detectedare in common. Only 27 proteins (13%)w ere unique to the plasma MPs (Fig. 5) .
Microparticlesare produced by several cellular processes including ectocytosis (blebbingofthe cell membrane) and release of exosomes. Ectocytosiscan occurinessentiallyall celltypes, particularly when theyare activatedorare undergoing apoptosis. Releaseofexosomes canoccur in most celltypes, particularly in culture, butisoften associated with cells of the immune system.
The physiologic functionsofplasma microparticlesinclude delivery of tissue factor to promote intravascular fibrin generation (18),pro-inflammatory functions (9, 24, 25) , alterations in vascular reactivity (15), induction of angiogenesis (16), intracellular communication (26), and perhaps certain anti-inflammatory functions(17). Plasma microparticlesare increased in many disease states (5),and their composition is changed as determined by flow cytometry(5, 27). The present study,for the first time, defines the protein composition of plasma microparticlesa s compared with platelet-derivedmicroparticlesusing LC/MS as an unbiased approach. As expected,m ost gene products identified in plasma MPsa re alsof ound in plateletm icroparticles, confirming thatmost plasma MPsare derivedfrom platelets (4). However, we found significant and potentiallybiologically important differences. Fora ll proteins detected with as pectral count of 10 or more, 21 were present almostexclusively in plasma MPs. In addition, twoproteinsw ere enrichedinthe protein MPsbyspectralcount and/or ICATanalysis.
Of these 23 proteins, some maybeconsideredtobecontamination by plasma proteins (marked PinTable 2).However,several linesofreasoning refutethis interpretation. First,ofthe five most abundantplasma proteins, albumin, IgG, transferrin, fibrinogen, and IgA (28),onlytwo,transferrinand albumin, were enriched in the plasma MPs versusthe plateletMPs basedonspectral counts. Albumin waspresentinrelativelylow amounts(45 th most abundantprotein)and some of this mayrepresent protein associatedwith platelets (29), or platelet MPs(20). Transferrin also hadalow spectral count (109 th most abundantprotein)and its receptor,amembrane protein, presumably in exosomes (30) (seebelow)had almost doublethe spectralcounts. Second,the plasma-derived proteins detected in the plasma MPs are nota random collection as would be expected of ac ontaminant. For example, sevenofthese proteins areassociatedwith apoptosis of cells, suggesting the clearance of these apoptotic cells or possibly the prevention of apoptosis in cells thath avec omplement components attached (2, 31). Four of the proteins in plasma MPs, complement 3, complement 4B,complement 4-binding proteins α and β ,are from the complement pathway.One mechanism by whichnucleatedcells prevent complement-induced celldeathis by shedding the complement components offofthe membrane (2).The complement components detectedi no ur study could represent MPsgenerated by sub-clinical autoimmune processes. Complement C3 is the most importantcomplement component that canbeactivatedbyany of the threedistinctpathways, classical( antibody-initiated),l ectin (microbe-initiated) and alternative pathways(32). The most likelyexplanation for the presenceo fc omplement proteins is sub-clinicala ctivation of the classicalpathway,which includes C3 and C4, by autoantibodies. Sub-clinical levels of autoantibodiesare widelyfound in healthy individuals( 33). Someo ft hem include so-called natural antibodies, for example, to blood group antigens (33).O thers are against certain pathogens suchas Streptococcus pneumoniae and cross-reactw ith endogenous oxidized lipids sucha so xLDL (34).However,C4isinvolved in both the lectin and the classical pathways, so we cannot excludethat intestinal or other commensal flora mayprovide astimulus for sub-clinical complement activation thatl eads to expulsion of complement-bound membranes into microparticles. C4BP (C4-bindingprotein)isapo- Twoo therp roteinse nriched in plasma MPs, CD5-like antigenand galectin 3-binding protein also are associatedwith inhibition of apoptosis. CD5-likeantigen, also called SP-α ,has notbeen extensively studied, butits mousehomolog,AIM(apoptosis inhibitor in macrophages), has several informative studies (37,3 8) . Macrophages of mice deficient in liverXr eceptors (LXRs) undergo accelerated apoptosis when challengedw ith Listeria monocytogenes,w hich is highlyd ependento nAIM, a direct target for regulation by LXRα (37). Similarly, thrombocytesshowincreased susceptibilitytoapoptosisinmicelacking AIM (38).Galectin 3-binding protein, also calledMac-2-binding protein, associateswith galectin 3, whichincreases cellular resistancet oa poptosis( 39, 40). The presenceo fa ll these proteins in plasma MPs suggests thats ome of these particles are eitherderivedfrom apoptotic cells or an indication thatmicroparticlesare shed to prevent apoptosis. Thesetwo mechanisms of production cannot be distinguishedinthe current study.
Another and more surprising set of proteins associatedwith plasma MPs is related to iron transport and hemoglobin clearance: transferrin, transferrinreceptor,haptoglobin,haptoglobinrelated protein, and hemoglobin.W hile transferrin is av ery abundantplasma protein, it most likelydoes not represent aplasma contaminant in plasma MPs, becausei ts receptor,am embrane protein, is also present, with almost double the spectral count.The transferrin receptor regulatest he uptakeo fi ron by most cells (41). During the maturing of reticulocytes, iron uptake decreasesdue to decreasedtransferrinreceptor on their cellsurface (30).Investigatorsexamining the loss of this receptor from the cell surfacewere some of the first to describe the releaseof exosomes (42, 43). Therefore, transferrin receptor in plasma MPs mayr epresent shedding of materiald uring reticulocyte maturation. The transferrin present in microparticlesc ould simplyresultfrom its binding to free microparticles. Haptoglobin is an abundantp rotein thatb inds free hemoglobin which would otherwise be toxic to cells,especially in the kidney (44). Theh aptoglobin knockoutm ouse did not impair clearanceo f free plasmah emoglobin butw as mores usceptible to oxidative damage and failedtorepairorregeneratedamaged renal tissues (45). It is possible thathaptoglobin removeshemoglobin by associating with plasma MPs. Indeed,hemoglobin wasdetected by our analysis in both plasma MPs and platelet MPs, suggesting thath aptoglobin-hemoglobin complexes maya ssociate with MPs.
The third categoryofplasma proteins overexpressedinplasma MPs areimmunoglobulins, representedb yimmunoglobulin (Ig)Jchain andkappa chain.This is not arandom selection of immunoglobulins, again makingplasma contamination alesslikely explanation. IgJ is associated with IgM, which includes all natural antibodies.A lsoe nriched ares everal complementc omponents, as discussedabove.These findings areconsistent with our proposal thatmicroparticlesreflect thesub-clinical activation of the classical complementpathwayatalowlevel through IgM auto-antibodies, leadingtothe formation of microparticlesfrom unknowncells(not platelets) thatremove IgJ andassociated complement components from the affected cell membrane.
Four proteins overexpressedinplasma MPs compared to plateletMPs are associatedwith lipoproteins(marked LinTable 2). Unliket he othersd escribed above,t hese most likelyr epresent contamination of plasma MPs with the larger plasma lipoproteins of the chylomicrons(apo A-I and C-III), chylomicron remnants (apo E), VLDL (apo A-I, B100, and C-III) and IDL (apo B100a nd E) fractions.P lasma lipoproteinsa ppeari no verlapping fractionswith microparticles, becausetheir sizesand therefore, their gel filtration propertiesare similartoMPs (datanot shown).While theys hould remain in the supernatant after the final centrifugation step, their contamination with the pellet is difficulttoavoid. In addition to the fourlipoproteinsfound overexpressed in plasma microparticles, apolipoprotiens A-II, C-II, L-I, and Lp(a), were found only in the plasma MPs butt he number of spectra for each wasbelow 10, and were notexamined further.
Three plasmap roteinsa ssociatedw ith blood coagulation, protein S, factor VIII,and vWF,(denotedP ,CinT able 2) were alsoenriched in plasma MPscompared to plateletMPs. While the best known roleofprotein Sisasananti-coagulant, it also is associated with apoptosis, as describedabove,and this likelyexplains its presenceinplasma MPs. Factor VIII is pro-coagulant, and the reasonfor its presenceisunknown. While it has beenreported thatfactor VIII bindsdirectly to Protein S(46), the significance of this to its presenceinplasma MPs is unclear.
vWF is aplateletand endothelial cell productthat binds to P-selectin (47),G P1b (48)a nd GP IIb/IIIa( 49). Since we previouslydetected vWF in plateletMPs (20), its presence in both plasma and platelet MPs in this study wasnosurprise. However, its enrichment in plasma MP wasunexpected and suggests that endothelial vWF associates with plasma MPsorevenpromotes their formation. Arecent study hasdemonstrated thatmicroparticlesa re indeed formed fromp latelets bound to immobilized vWF under high shear stress, in vitro (50). EndothelialvWF is secreted fromW eibel-Palade bodies and has been shown to be present in endothelial-derivedM Ps underd iseasec onditions (51).I te xistsa savery largem ultimer and is cleaved by ADAMTS-13 (52). These data are consistent withour observation thatp lasma-derivedM Ps are enrichedf or vWF.O ur proteomic analysis doesn ot distinguishb etween monomers and multimers, so furtherwork will be needed to identify the nature of the vWF associated with plasma MPs. The association of coagulation factorsand platelet-binding factorsisentirelyconsistent with the ideat hat plasma MPsa re ap ro-coagulant surface (11) and associate with nascent thrombi (18, 19) .
FCGBP is aprotein with unknown function produced by intestinala nd colonic goblet cells (53, 54). Due to its cellular sourceand its ability to bind IgG,ithas been hypothesizedtoassist in preventing antigeninvasion into the mucosa (53,55). Kobayashi et al. found that FCGBP could inhibitacomplement-mediated reaction and suggested thatitmay playanimportant role in immunological defenseofmucosalsurfaces (55).While this follows our theories of ectosomep roduction previously discussed, there is little evidencetosupportthe connection between FCGBP and the prevention of celldeathinvascular tissue.This is particularly true considering the location of FCGBP production. However, the detection of this protein in plasma MPs is very intriguingespecially when oneconsiders its prevalence(spectral count of 167including 54 unique peptides).
The remaining protein, tenascin Cisanextracellular matrix protein associated with provisional and tumor matrices butnot found in most mature tissues (56).Itispossible that tenascin Cis secreted at sites of small injuriesand wound healing, and cells with rapid turnovers uch as leukocytes and wound fibroblasts mays hed tenascin Ca ssociatedw ith MPs. Alternatively, tenascinCmay formaggregatesthat migrate in the MP fraction. Its presencewas unexpected in the plasma MP fraction and further studies areneeded to examine its implications.
Equallya si nteresting as the overexpressed gene products in plasmas MPs is the absence of detection of knowncomponents. Tissuefactorisinplasma-derivedmicroparticles(18), as shown by We sternblot (57) and intravital microscopy(18), yetwecould not detect this initiator of coagulation. This could be due to itslow abundance, small cytoplasmic tail or to glycosylation of the extracellular domains (58).Glycosylated proteinsare difficult to identifyb ystandard proteomic analysis,asconductedhere. Asecond interestingpoint is thatnocell-specific proteins were detected as clearly overexpressed in plasma MPs. This reinforces the notion that plasma MPs in healthypeople aremostlyplatelet-derived(4) andthus not very different from plateletMPs. However, we did detectp roteins specificf or endothelial cells( endothelial cell adhesion molecule),smooth muscle cell proteins (enolase-3, hexokinase 2),a nd erythrocytes( beta spectrin, erythrocyte membrane protein band 4.9 [dematin]) butwecould not establish statistically significanto verexpression in plasmaM Ps compared to platelet MPs due to their lows pectral counts or lowi on intensities by ICAT. This mayr eflect their minor contribution to the overall population of plasmaM Ps ande mphasizest he need of complementing unbiased masss pectrometrya nalysisw ith ac andidatebased flowcytometryormass spectrometryapproach (6, 18).
In conclusion,the present reportestablishes significant differences between plasma-a nd platelet-derivedm icroparticle proteins. Al arge majority of these differences are proteins involved with apoptosis or iron transport.Itisreassuring thatvery fewproteinsw ere detected in plasma MPs thatcould be classified as plasma contaminants. While it is likelythat most of these proteins arepresentduring the formation of microparticles, other proteins could bind following release into the plasma. These studies do not distinguishbetween these twomechanisms. In studying the biology of complement,c oagulation and other processes, microparticlesw ill have to be considereda si mportant contributorsfor removing such components from cells.Sources of the proteins found in plasma-derived MPs onlymay be useful biomarkersfor variousdiseaseprocesses. Supplementary tables for TH-06-02-0066, "Proteomic discovery of 21 proteins expressed in human plasma-derived but not platelet-derived microparticles" by David M. Smalley et al. 
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